Global Nuclear Medicine (Medical Isotopes/ Radioisotopes/ Radiopharmaceuticals) Market in PET/SPECT Imaging and Therapy - Competitive Landscape, Current trends and Forecasts (2010 - 2015)
NEW YORK, Sept. 7, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0595075/Global-Nuclear-Medicine-Medical-Isotopes/-Radioisotopes/-Radiopharmaceuticals-Market-in-PET/SPECT-Imaging-and-Therapy---Competitive-Landscape-Current-trends-and-Forecasts-2010-–-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging
Report Description:
Radiopharmaceuticals Therapy and PET/SPECT Imaging – A Global Scenario (2010-2015)
Radiopharmaceuticals are pharmaceutical agents used to diagnose certain medical problems such as cardiac, cancer, neurology, and/or treat certain conditions such as cancers. The use of radiopharmaceuticals as tracer dates back to 1930's. Over the years, technical advancement in production, diagnostic equipments (SPECT and PET), and discovery of new radiopharmaceutical have driven the market. The global radiopharmaceuticals market for therapy and PET & SPECT imaging was valued at $3,213 million in 2010 and is expected to reach $4,734 million by 2015; growing at a CAGR of 8.1% from 2010 to 2015. The PET & SPECT diagnosis accounted for the largest share -90%- of the global radiopharmaceutical market.
Diagnostic applications of radiopharmaceuticals have around 90% of the market share. The market is growing due to the increasing incidences of cancer and cardiac diseases, requisition of better imaging techniques for diseases such as Alzheimer's. Targeted alpha therapy is one of the most promising treatments for cancer, which is being researched upon by cancer institutes.
Driven by the increasing incidence of cardiac and cancer diseases, early and accurate diagnosis, increasing awareness amongst the masses, and expanding application segment; the global radiopharmaceutical market reached around $3.2 billion in 2010. Radiopharmaceuticals are used for the diagnosis and treatment of various ailments such as cancer, cardiac, renal, and respiratory diseases among the others. PET machines enable radiologists in early detection of cancer, cardiac, and Alzheimer's disease among the patients. This would increase the demand for PET machines among the healthcare centers and providers. Similarly, SPECT scanners have been on the forefront to bring about significant changes in the diagnostic imaging equipment landscape with opportunities in the market for neuroendocrine tumor imaging. For diagnostic applications of radiopharmaceuticals, radioisotopes such as FDG for PET and technetium for SPECT are most commonly used.
PET and SPECT scans provide dynamic images of the body's interior, rather than just the bones, like X-ray and magnetic resonance imaging (MRI). PET scan lets the doctor identify glucose metabolism in different parts of the body in a patient. Cancer cells grow at a faster rate than the other cells. The machine detects the speed of glucose being used and indicates the presence of cancerous tumors. The cancerous cell breaks down glucose at a higher rate than the other cells and this increased activity can be seen in a scan. Thus, the use of PET and SPECT scans facilitates early and accurate diagnosis of diseases such as cancer. Increased usage of PET & SPECT scans in turn increases the demand for radiopharmaceuticals.
FDG is the major radiopharmaceutical used in PET (approximately 90%). PET procedures are preferred over SPECT as PET is more accurate, sensitive, and endowed with better spatial arrangement of the image. Besides, the main radiopharmaceutical used in SPECT; i.e. technetium (99m) has a limited supply, forcing people to look for alternatives. FDG can be produced at desired levels to meet all the imaging requirements. This situation is boosting the FDG market.
Most of the radiopharmaceuticals are used in hospitals; accounting for 92%. Majority of the radiopharmaceuticals are administered intravenously. The market for radiopharmaceuticals is restricted by their high cost and difficulties faced while transporting them.
Scope of the report
This research report categorizes the radiopharmaceuticals therapy and PET/SPECT imaging market on the basis of isotopes, routes of administration, applications, and geography; forecasting revenue, and analyzing trends in each of the following submarkets:
On the basis of isotopes:
Fludeoxyglucose (F18), Technetium (Tc99m), Gallium (Ga67), Sodium Iodide (I123), Iobenguane (I131), Rhenium (Re186), Samarium (Sm153),Thallium (Tl201), Yttrium (Y90), Erbium(Er169), and others
On the basis of routes of administration:
Intravenous, peroral, inhalation, and others
On the basis of applications:
Diagnosis (PET and SPECT), indication for diagnosis, and therapy
On the basis of geography:
North America (U.S. and Canada), Europe, Asia-Pacific, Japan, and Rest of the World
Each section provides market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments. In addition, the report provides more than 16 company profiles covering all the sub-segments.
TABLE OF CONTENTS
Executive Summary
MARKET SCENARIO
1 Introduction
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
2 Summary
3 Market Overview
3.1 Definition of Radiopharmaceuticals
3.2 Evolution
3.3 Market Segmentation
3.4 Driving Force Analysis
3.4.1 Drivers
3.4.1.1 Increasing incidence of cancer and cardiac ailments
3.4.1.2 Increasing use of SPECT and PET scans
3.4.1.3 Rising awareness of Radiopharmaceuticals among physicians
3.4.1.4 Alpha radioimmunotherapy-based targeted cancer treatment
3.4.1.5 Ready availability of radiopharmaceuticals from cyclotrons
3.4.2 Restraints
3.4.2.1 Half-life of radiopharmaceuticals
3.4.2.2 High capital demand
3.4.2.3 Lack of good manufacturing practices (GMP)
3.4.2.4 Inefficient effluent treatment management
3.4.2.5 Stringent regulatory guidelines
3.4.3 Threat
3.4.3.1 Shutdown of nuclear reactors impacts the production of radioisotopes
3.4.4 Opportunities
3.4.4.1 Increasing demand for diagnosis
3.4.4.2 High demand in geographies with inadequate supply
3.5 Winning Imperatives
3.5.1 Introduction of new agents for the treatment of alzheimer's disease
3.5.2 Increasing regulatory approvals of radiopharmaceuticals
3.6 Burning Issues
3.6.1 High cost of imaging devices
3.6.2 Shortage in supply of technetium-99m (Radioisotope)
3.7 Market Share Analysis
3.8 End-User Analysis
3.9 Competitive Analysis
3.10 Patent Analysis
3.11 Future Radiopharmaceuticals
4 Radiopharmaceutical Market, by Isotopes
4.1 Introduction
4.2 Fludeoxyglucose (18F)
4.2.1 Increase in availability of hybrid pet/ct machines
4.2.2 Rise in pet procedures increases demand for FDG
4.2.3 High generation costs of FDG
4.2.4 Need for speedy & efficient transportation
4.3 Technetium (99MTC)
4.3.1 Technetium can combine with 31 different carrier molecules
4.3.2 Lack of availability of technetium
4.4 Thallium (201TL)
4.4.1 Thallium most common substitute of technetium
4.5 Gallium (67GA)
4.6 Sodium Iodide (123I)
4.7 Iobenguane (131I)
4.8 Rhenium (186RE)
4.9 Samarium (153SM)
4.10 Yttrium (90Y)
4.11 Erbium(169ER)
4.12 Others
5 Radiopharmaceutical Market, by Routes of Administration (ROA)
5.1 Introduction
5.2 Intravenous Administration
5.3 Inhalation Administration
5.4 Peroral Administration
5.5 Other Routes of Administration
6 Radiopharmaceutical Market, by Applications
6.1 Introduction
6.2 Radiopharmaceuticals for Diagnosis
6.2.1 Single-photon emission computed tomography (SPECT) imaging
6.2.1.1 Introduction
6.2.1.2 Principle & procedure
6.2.1.3 Radiotracers
6.2.1.4 Limitations
6.2.1.5 Safety
6.2.1.6 Radiopharmaceuticals
6.2.1.6.1 Technetium-99m
6.2.1.6.2 Erbium (169Er)
6.2.1.6.3 Gallium (67Ga)
6.2.1.6.4 Sodium iodide (123I)
6.2.1.6.5 Iobenguane (131I)
6.2.1.6.6 Rhenium (186Re)
6.2.1.6.7 Samarium (153Sm)
6.2.1.6.8 Thallium (201Tl)
6.2.1.6.9 Yttrium (90Y)
6.2.1.6.10 Others
6.2.2 Positron emission tomography (PET) imaging
6.2.2.1 Introduction
6.2.2.2 Principle & procedure
6.2.2.3 Radiotracers
6.2.2.4 Limitations
6.2.2.5 Safety
6.2.2.6 Radiopharmaceuticals
6.2.2.6.1 18F-FD/Fluorodeoxyglucose (18F)
6.2.2.6.2 Others
6.3 Radiopharmaceutical Market, by Indication for Diagnosis
6.3.1 Introduction
6.3.2 Cardiac diseases
6.3.3 Neuroimaging
6.3.4 Bone scan
6.3.5 Liver scan
6.3.6 Respiratory scan
6.3.7 Renal scan
6.3.8 Thyroid scan
6.4 Radiopharmaceuticals for Treatment/Radionuclide Therapy (RNT)
6.4.1 Targeted alpha therapy (TAT) or alpha radioimmunotherapy
6.4.2 Radiopharmaceuticals
6.4.2.1 Iobenguane (131I)
6.4.2.2 Rhenium (186Re)
6.4.2.3 Samarium (153Sm)
6.4.2.4 Others
7 Regulatory Challenges for Radiopharmaceutical's Production
7.1 Introduction
7.2 Safety of Personnel
7.3 Equipment & Facility
7.4 Transportation Guidelines
7.5 Guidelines in Europe
7.6 Guidelines in U.S.
7.7 Reimbursement
8 Geographic Analysis (Consumption)
8.1 Introduction
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.4 APAC (Excluding Japan)
8.5 Japan
8.6 Rest of the World (ROW)
9 Geographic Analysis (Production)
9.1 Introduction
9.2 North America
9.3 Europe
9.4 APAC (Excluding Japan)
9.5 Japan
9.6 Rest of the World
10 Competitive Landscape
11 Company Profiles
11.1 AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO)
11.1.1 Overview
11.1.2 Products & services
11.1.3 Financials
11.1.4 Strategy
11.1.5 Developments
11.2 BOARD OF RADIATION AND ISOTOPE TECHNOLOGY (BRIT)
11.2.1 Overview
11.2.2 Products & services
11.3 CARDINAL HEALTH INC
11.3.1 Overview
11.3.2 Products & services
11.3.3 Financials
11.3.4 Strategy
11.3.5 Developments
11.4 COVIDIEN PLC
11.4.1 Overview
11.4.2 Products & services
11.4.3 Financials
11.4.4 Strategy
11.4.5 Developments
11.5 ECZACIBASI-MONROL
11.5.1 Overview
11.5.2 Products & services
11.5.3 Strategy
11.5.4 Financials
11.5.5 Development
11.6 FUJIFILM HOLDINGS CORP
11.6.1 Overview
11.6.2 Products & services
11.6.3 Financials
11.6.4 Strategy
11.6.5 Developments
11.7 GE HEALTHCARE
11.7.1 Overview
11.7.2 Products & services
11.7.3 Financials
11.7.4 Strategy
11.7.5 Developments
11.8 IBA GROUP
11.8.1 Overview
11.8.2 Products & services
11.8.3 Financials
11.8.4 Strategy
11.8.5 Developments
11.9 INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE (POLATOM)
11.9.1 Overview
11.9.2 Products & services
11.9.3 Strategy
11.9.4 Developments
11.10 INSTITUTE OF ISOTOPES CO. LTD.
11.10.1 Overview
11.10.2 Products & services
11.10.3 Strategy
11.11 INSTITUTE OF RADIOELEMENT (IRE)
11.11.1 Overview
11.11.2 Products & services
11.11.3 Strategy
11.11.4 Developments
11.12 LANTHEUS MEDICAL IMAGING INC
11.12.1 Overview
11.12.2 Products & services
11.12.3 Financials
11.12.4 Strategy
11.12.5 Developments
11.13 NORDION INC
11.13.1 Overview
11.13.2 Products & services
11.13.3 Financials
11.13.4 Strategy
11.13.5 Developments
11.14 NTP RADIOISOTOPES (PTY) LTD
11.14.1 Overview
11.14.2 Products & services
11.14.3 Financials
11.14.4 Strategy
11.14.5 Developments
11.15 SAMYOUNG UNITECH CO. LTD
11.15.1 Overview
11.15.2 Products & services
11.15.3 Financials
11.15.4 Strategy
11.16 SIEMENS HEALTHCARE
11.16.1 Overview
11.16.2 Products & services
11.16.3 Financials
11.16.4 Strategy
11.16.5 Developments
APPENDIX
• U.S. Patents
• Europe Patents
• Japan Patents
• Wipo Patents
LIST OF TABLES
1 Global Radiopharmaceutical Market Revenue,
by Applications, 2008 – 2015 ($Million)
2 Radiopharmaceutical Market Revenue, by Geography,
2008 – 2015 ($Million)
3 Radiopharmaceuticals in Clinical Trials
4 Radiopharmaceuticals Segmentation
5 Global Radiopharmaceuticals Market Revenue, by Types,
2008 – 2015 ($Thousand)
6 Radiopharmaceuticals Market Revenue, by Geography,
2008 – 2015 ($Million)
7 North America: Radiopharmaceutical Market Revenue,
by Countries, 2008 – 2015 ($Million)
8 FDG Market Revenue, by Geography, 2008 – 2015 ($Thousand)
9 North America: FDG Market Revenue, by Countries, 2008 – 2015 ($Thousand)
10 Indications Diagnosed by Technetium
11 Technetium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
12 North America: Technetium Market Revenue, by Countries, 2008 – 2015 ($Thousand)
13 Thallium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
14 North America: Thallium Market Revenue, by Countries,
2008 – 2015 ($Thousand)
15 Gallium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
16 North America: Gallium Market Revenue, by Countries,
2008 – 2015 ($Thousand)
17 Sodium Iodide Market Revenue, by Geography, 2008 – 2015 ($Thousand)
18 North America: Sodium Iodide Market Revenue, by Countries, 2008 – 2015 ($Thousand)
19 Iobenguane Market Revenue, by Geography, 2008 – 2015 ($Thousand)
20 North America: Iobenguane Market Revenue, by Countries, 2008 – 2015 ($Thousand)
21 Rhenium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
22 North America: Rhenium Market Revenue, by Countries,
2008 – 2015 ($Thousand)
23 Samarium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
24 North America: Samarium Market Revenue, by Countries,
2008 – 2015 ($Thousand)
25 Yttrium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
26 North America: Yttrium Market Revenue, by Countries,
2008 – 2015 ($Thousand)
27 Erbium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
28 North America: Erbium Market Revenue, by Countries,
2008 – 2015 ($Thousand)
29 Others Market Revenue, by Geography, 2008 – 2015 ($Thousand)
30 North America: Others Market Revenue, by Countries,
2008 – 2015 ($Thousand)
31 Global Radiopharmaceuticals Route of Admnistration Market Revenue, by Types, 2008 – 2015 ($Million)
32 Radiopharmaceuticals Route of Administration Market Revenue, by Geography, 2008 – 2015 ($Million)
33 North America: Radiopharmaceuticals Route of Administration Market Revenue, by Countries, 2008 – 2015 ($Million)
34 Intravenous Route of Administration Market Revenue,
by Geography, 2008 – 2015 ($Million)
35 North America: Intravenous Route of Administration Market Revenue, by Countries, 2008 – 2015 ($Million)
36 Inhalation Route of Administration Market Revenue,
by Geography, 2008 – 2015 ($Million)
37 North America: Inhalation Route of Administration Market Revenue, by Countries, 2008 – 2015 ($Million)
38 Peroral Route of Administration Market Revenue,
by Geography, 2008 – 2015 ($Thousand)
39 North America: Peroral Route of Administration Market Revenue, by Countries, 2008 – 2015 ($Thousand)
40 Other Types of Routes of Administration
41 Other Routes of Administration Market Revenue,
by Geography, 2008 – 2015 ($Million)
42 North America: Other Routes of Administration Market,
by Countries, 2008 – 2015 ($Million)
43 Global Diagnostic Radiopharmaceuticals Market Revenue,
by Types, 2008 – 2015 ($Million)
44 Diagnostic Radiopharmaceuticals Market Revenue,
by Geography, 2008 – 2015 ($Million)
45 North America: Diagnostic Radiopharmaceuticals Market,
by Countries, 2008 – 2015 ($Million)
46 Global SPECT Radiopharmaceuticals Market, by Types,
2008 – 2015 ($Thousand)
47 SPECT Radiopharmaceuticals Market Revenue, by Geography, 2008 – 2015 ($Million)
48 North America: SPECT Radiopharmaceuticals Market Revenue, by Countries, 2008 – 2015 ($Million)
49 Technetium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
50 North America: Technetium Market Revenue, by Countries, 2008 – 2015 ($Thousand)
51 Erbium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
52 North America: Erbium Market Revenue, by Countries,
2008 – 2015 ($Thousand)
53 Gallium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
54 North America: Gallium Market Revenue, by Countries,
2008 – 2015 ($Thousand)
55 Sodium Iodide Market Revenue, by Geography, 2008 – 2015 ($Thousand)
56 North America: Sodium Iodide Market Revenue, by Countries, 2008 – 2015 ($Thousand)
57 Iobenguane Market Revenue, by Geography, 2008 – 2015 ($Thousand)
58 North America: Iobenguane Market Revenue, by Countries, 2008 – 2015 ($Thousand)
59 Rhenium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
60 North America: Rhenium Market Revenue, by Countries,
2008 – 2015 ($Thousand)
61 Samarium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
62 North America: Samarium Market Revenue, by Countries,
2008 – 2015 ($Thousand)
63 Thallium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
64 North America: Thallium Market Revenue, by Countries,
2008 – 2015 ($Thousand)
65 Yttrium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
66 North America: Yttrium Market Revenue, by Countries,
2008 – 2015 ($Thousand)
67 Others Market Revenue, by Geography, 2008 – 2015 ($Thousand)
68 North America: Others Market Revenue, by Countries,
2008 – 2015 ($Thousand)
69 Global Pet Radiopharmaceuticals Market Revenue, by Types, 2008 – 2015 ($Million)
70 Pet Radiopharmaceuticals Market Revenue, by Geography, 2008 – 2015 ($Million)
71 North America: Pet Radiopharmaceuticals Market,
by Countries, 2008 – 2015 ($Million)
72 FDG Market Revenue, by Geography, 2008 – 2015 ($Thousand)
73 North America: FDG Market Revenue, by Countries, 2008 – 2015 ($Thousand)
74 Others Market Revenue, by Geography, 2008 – 2015 ($Thousand)
75 North America: Others Market Revenue, by Countries,
2008 – 2015 ($Thousand)
76 Treatment Radiopharmaceuticals Market Revenue, by Types, 2008 – 2015 ($Thousand)
77 Treatment Radiopharmaceuticals Market Revenue,
by Geography, 2008 – 2015 ($Thousand)
78 North America: Treatment Radiopharmaceuticals Market Revenue, by Countries, 2008 – 2015 ($Thousand)
79 Iobenguane Market Revenue, by Geography, 2008 – 2015 ($Thousand)
80 North America: Iobenguane Market Revenue, by Countries, 2008 – 2015 ($Thousand)
81 Rhenium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
82 North America: Rhenium Market Revenue, by Countries,
2008 – 2015 ($Thousand)
83 Samarium Market Revenue, by Geography, 2008 – 2015 ($Thousand)
84 North America: Samarium Market Revenue, by Countries,
2008 – 2015 ($Thousand)
85 Other Radiopharmaceuticals, by Types
86 Others Market Revenue, by Geography, 2008 – 2015 ($Thousand)
87 North America: Others Market Revenue, by Countries,
2008 – 2015 ($Thousand)
88 North America: Radiopharmaceuticals Market Revenue,
by Radioisotopes, 2008 – 2015 ($Thousand)
89 U.S: Radiopharmaceuticals Market Revenue,
by Radioisotopes, 2008 – 2015 ($Thousand)
90 Canada: Radiopharmaceuticals Market Revenue,
by Radioisotopes, 2008 – 2015 ($Thousand)
91 Europe: Radiopharmaceuticals Market Revenue,
by Radioisotopes, 2008 – 2015 ($Thousand)
92 APAC: Radiopharmaceuticals Market Revenue,
by Radioisotopes, 2008 – 2015 ($Thousand)
93 Japan: Radiopharmaceuticals Market Revenue,
by Radioisotopes, 2008 – 2015 ($Thousand)
94 Row: Radiopharmaceuticals Market Revenue,
by Radioisotopes, 2008 – 2015 ($Thousand)
95 Mergers & Acquisitions
96 Agreements & Collaborations
97 New Product Development
98 New Expansion Facilities
99 Approvals
100 Ansto Health: Market Revenue, 2008 – 2010 ($Million)
101 Cardinal: Market Revenue, 2008 – 2010 ($Million)
102 Cardinal: Market Revenue, by Segments, 2008 – 2010 ($Million)
103 Covidien: Market Sales and R&D Expenses, 2008 – 2010 ($Million)
104 Covidien: Market Sales, by Segments, 2008 – 2010 ($Million)
105 Covidien: Market Revenue, by Segment, 2008 – 2010 ($Million)
106 Covidien: Revenue, by Geography, 2008 – 2010 ($Million)
107 Fujifilm: Market Revenue, 2009 – 2011 ($Million)
108 Fujifilm: Market Revenue, by Segments, 2009 – 2011 ($Million)
109 Fujifilm: Medical System Segment Revenue, 2009 – 2011 ($Million)
110 Fujifilm: Market Revenue, by Geography, 2009 – 2011 ($Million)
111 GE Healthcare: Market Revenue and R&D Expenses, 2007 – 2009 ($Billion)
112 GE Healthcare: Market Revenue, by Segment, 2007 – 2009 ($Billion)
113 GE Healthcare: Market Revenue, by Geography, 2007 – 2009 ($Billion)
114 IBA Group: Total Market Revenue, 2008 – 2010 ($Million)
115 IBA Group: Market Revenue, by Segments, 2008 – 2010 ($Million)
116 IBA Group: Market Revenue, by Geography, 2008 – 2010 ($Million)
117 Lantheus: Market Revenue and R&D Expenses 2008 – 2010 ($Thousand)
118 Lantheus: Market Revenue, by Segments, 2008 – 2010 ($Thousand)
119 Lantheus: Market Revenue, by Geography, 2008 – 2010 ($Thousand)
120 Nordion: Market Revenue and R&D Expenses, 2008 – 2010 ($Million)
121 Nordion: Market Revenue, by Segments, 2008 – 2010 ($Million)
122 Nordion: Market Revenue, by Countries, 2008 – 2010 ($Million)
123 Siemens Healthcare: Total Market Revenue, 2008 – 2010 ($Million)
124 Siemens Healthcare: Market Revenue, by Segments, 2008 – 2010 ($Million)
LIST OF FIGURES
1 Radiopharmaceutical Market, by Radioisotopes, (2008 – 2015)
2 Evolution in Radiopharmaceuticals
3 Radiopharmaceuticals: Market Segmentation
4 Factors Driving the Radiopharmaceuticals Market
5 Radiopharmaceutical Market Share Analysis, 2010
6 Analysis of Radiopharmaceuticals Market, by End-Users, 2010
7 Competitive Landscape for Radiopharmaceuticals Market
8 Patent Analysis, by Assignee, 2005 – 2010
9 Global Radiopharmaceuticals Market Share, by Production
10 Global Radiopharmaceuticals Market: Competitive Landscape
To order this report:
Medical Imaging Industry: Global Nuclear Medicine (Medical Isotopes/ Radioisotopes/ Radiopharmaceuticals) Market in PET/SPECT Imaging and Therapy - Competitive Landscape, Current trends and Forecasts (2010 – 2015)
Medical Imaging Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article